Study of Brain-Gut Neurometabolic Networks for Predicting Outcomes in Colorectal Cancer

What this Trial Is About

Colorectal cancer CRC is a leading cause of cancer-related death worldwide, with a complex development process involving genetic and environmental factors. This research aims to explore the role of brain-gut interactions, particularly neuro-metabolism, in the development and progression of CRC. The study focuses on understanding how brain networks and metabolic processes may influence tumor growth and spread, which could help identify new diagnostic and treatment strategies for CRC. The study uses advanced imaging techniques like 18F-FDG PETCT scans to examine brain metabolism and its connection to CRC. Participants diagnosed with colorectal adenocarcinoma will have their PETCT images collected and analyzed to assess the prognostic value of a neurometabolic network model called BRIDGE. This observational study compares BRIDGEs predictive ability for overall survival with traditional clinical models. Participants will undergo PETCT imaging within 1 to 2 weeks after enrollment, with images anonymized and centrally reviewed for quality. Researchers will collect clinical data and follow patients to evaluate survival outcomes. The primary measure is the area under the curve AUC for BRIDGE in predicting overall survival. The study will run from March 2024 to December 2026, aiming to provide insights into brain metabolisms role in CRC prognosis and support future tailored therapies.

Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC)